Oxidative rearrangements during fungal biosynthesis

Russell Cox*[ab]

Covering: 1942–2014

Oxidative rearrangements are key reactions during the biosyntheses of many secondary metabolites in fungi. This review highlights the most important examples of these reactions and aims to draw together key mechanistic themes to allow a better understanding and future exploitation of this key class of fungal catalysts.

1   Introduction and scope

Fungi produce natural products with arguably the greatest range of structural complexity of all micro-organisms. They achieve this using much the same 'standard' machinery as other organisms, using: polyketide synthases (PKS); ribosomal synthesis and non-ribosomal peptide synthetases (NRPS); and terpene cyclases *etc.* These basic skeletons are then diversified using highly selective tailoring reactions. In fungi these

tailoring steps are very often oxidative, and an important subset of these oxidative reactions are those which also include a skeletal rearrangement. Such reactions are known in synthetic chemistry, but their scope and selectivity are limited compared to those observed in fungi. This review will cover the most important of these biosynthetic transformations – it does not set out to be comprehensive, but to illustrate the relationships between the best known oxidative rearrangements. It is no coincidence that the review appears in this particular issue *Natural Product Reports* since the contributions of Professors Simpson, Vederas and Townsend have been seminal to development of the subject.

2   Cephalosporins

The production of β-lactams provides one of the most compelling examples of the power of selective oxidations during biosynthesis. The tripeptide ACV **1** is first oxidised twice by a single equivalent of dioxygen, catalysed by the enzyme iso-penicillin-N-synthase (IPNS) to form the bicyclic penicillin skeleton **2**. While the reaction catalysed by IPNS is oxidative, it is not strictly a rearrangement and will not be discussed here (IPNS has been recently and comprehensively reviewed elsewhere).[1] A distal epimerisation of **2** giving penicillin N **3** is then followed by an oxidative rearrangement to provide the cephalosporin C skeleton (Scheme 1).

The rearrangement is known to occur both in fungi (*e.g. Acremonium chrysogenum*, also known as *Cephalosporium acremonium*) and bacteria (*e.g. Streptomyces clavuligerus*). In bacteria the rearrangement is catalysed by an enzyme known as deacetoxycephalosporin C synthase (DAOCS) – a second oxidase then catalyses hydroxylation at the 3′ methyl position (deacetylcephalosporin C synthase, DACS). In fungi both transformations are performed by a single bifunctional enzyme (known as DAOCS/DACS).

aInstitute for Organic Chemistry, Leibniz University of Hannover, Schneiderberg 1B, 30167 Hannover, Germany. E-mail: russell.cox@oci.uni-hannover.de

bSchool of Chemistry, University of Bristol, Cantock's Close, Clifton, Bristol, BS8 1TS, UK. E-mail: r.j.cox@bristol.ac.uk

This journal is © The Royal Society of Chemistry 2014

Nat. Prod. Rep., 2014, **31**, 1405–1424 | 1405

Scheme 1 Overall pathway from ACV **1** to cephalosporin C **6**. Enzymes: (i), isopenicillin N synthase; (ii), isopenicillin N epimerase; (iii), deacetoxycephalosporin C synthase; (iv), deacetylcephalosporin C synthase; (v), acetyl–coenzyme A:DAC O-acetyltransferase.

2.1 Isotopic labelling experiments

Early work using cell-free extracts of *A. chrysogenum*[2] showed that an impure enzyme fraction could be prepared which possessed the ring-expanding activity and which was stimulated

Russell Cox was born in 1967 in the New Forest in the UK where he grew up. He studied chemistry at the University of Durham, and then worked with Prof. David O'Hagan at the same institution for his Ph.D., studying the biosynthesis of fungal metabolites. Post-doctoral periods with Professor John Vederas FRS in Edmonton Alberta, and Professors David Hopwood FRS and Tom Simpson FRS at Norwich

and Bristol in the UK were followed by his appointment as a lecturer in the School of Chemistry at the University of Bristol where he rose to become Professor of Organic and Biological Chemistry. Russell Cox moved to become Professor of Microbiological Chemistry at the Leibniz Universität Hannover in Germany in 2013. He served as an editorial board member of Natural Product Reports *until 2012, and is currently an editorial board member of* RSC Advances.

by iron, α-ketoglutarate[3] and ascorbate – typical of non-heme iron dioxygenases.[4] Isopenicillin N **2** was shown to be the direct substrate, ruling out parallel pathways from ACV to **3** and **6**.[5] Pioneering synthesis by Baldwin and coworkers of (2RS,3R)-[4-^{13}C]-valine **7a** allowed the first investigations of the stereoselectivity of the ring expansion to be performed.[6] ^{13}C NMR was used to show that the labelled valine was incorporated into both the penicillin skeleton and into cephalosporin C **6**. Specifically, the ^{13}C label was incorporated into the β-methyl position of penicillin V isolated from *Penicillium chrysogenum* and into the 2-position of Cephalosporin C **6** from *A. chrysogenum* suggesting that the ring expansion must selectively incorporate the β-methyl group into the thiopyran ring of cephalosporin.[7] Later the same year Sih and Abraham reported the synthesis of (2S,3S)-[4-^{13}C]-valine **7b** and showed that the label is incorporated into the α-methyl of penicillin N **3** and the 3′-methylene of cephalosporin C **6** (Scheme 2A).[8]

Townsend and coworkers investigated the stereochemical fate of the 3-*pro-R* methyl group of valine during the ring expansion reaction (Scheme 2B and C). They synthesised both (2RS,3R,4R)**8** and (2RS,3R,4S)-[4-^{2}H,^{3}H]valine[9] **9** and fed them to growing cultures of *Acremonium strictum*. The prior work of Baldwin and others already showed that the 3-*pro-R* methyl of valine is incorporated into the ring during expansion with clean retention of configuration at C-3. Townsend's results showed that, in contrast, stereochemical integrity at the β-2-methyl of penicillin N **3** is lost, showing that the ring expansion proceeds with complete epimerization (Scheme 2B).[10] This loss of stereochemical integrity, however, is not a feature intrinsic to the fungal DAOCS/DACS enzyme because in a parallel series of experiments it was shown that hydroxylation at the 3′ carbon of deacetoxycephalosporin C **5**, performed by the same enzyme, proceeds with retention of stereochemistry (Scheme 2C).[11]

These results were interpreted as an indication that the first step of the rearrangement is the abstraction of a hydrogen atom from the β-methyl group of **3** by a typical iron(IV) oxo species, and formation of a methylene radical **10** which rapidly rotates (thus scrambling the label to **11**) before the next step. In the case of abstraction of a hydrogen atom from the 3′ methyl of **4**, the formed methylene radical **12** cannot rotate (or at least rotates more slowly than competing hydroxylation), probably because of conjugation of the methylene radical to the adjacent olefin, and thus hydroxylation occurs with retention of stereochemistry giving **5** (Scheme 3).

It was already known that growing cultures of *C. acremonium* produced the hydrated deacetoxycephalosporin C analogue **13** in low titre (Scheme 4). This compound is also produced *in vitro* using purified DAOCS/DACS (around 1.6% of the total ring-expanded products) showing that it is produced by the enzyme rather than by another activity of the whole organism. Baldwin and coworkers reported an intriguing observation when they used [3-^{2}H] penicillin N **3a** as the *in vitro* substrate of DAOCS/DACS.[12] In this case **13** was produced as 35% of the total ring expanded product. This result was interpreted as indicating the presence of a thiranyl cation or radical intermediate such as **14** (Scheme 4). Elimination of the 3-hydrogen would lead to the major product **4**, but operation of a significant isotope effect

1406 | *Nat. Prod. Rep.*, 2014, **31**, 1405–1424

This journal is © The Royal Society of Chemistry 2014

Scheme 2 Results of isotopic feeding studies using chiral valines.

Scheme 3 Hydrogen abstraction reactions catalysed by DAOCS/DACS. Iron ligands not shown for clarity. See Scheme 6 for a more detailed proposed mechanism of the ring expansion.

Scheme 4 Effect of ^{2}H at the 3-position of penicillin N **3a** during the ring expansion.

could slow this route and allow hydroxylation to give **13**. Hydroxylation on the top face of the cepham skeleton is consistent with the proposed position of the enzyme's iron hydroxyl species. Labelling with $^{18}O_2$ showed that the introduced oxygen of **13** does indeed come from this source. **13** is not a substrate for further 3′ oxidation by DAOCS/DACS, and although not explicitly reported, seems unlikely to be an intermediate on the pathway to **6** itself.

Further mechanistic insight into the ring expansion is scant – but information from two sources has been used to formulate a plausible hypothesis. First, biomimetic reactions have been performed *in vitro* which provide information about possible mechanisms. Second, and more latterly, structural data has been obtained from the bacterial DAOCS.

2.2 Biomimetic reactions

The chemical conversion of penicillin N **3** to cephalosporin C **6** was first achieved by Morin and coworkers at Lilly.[13] The Morin rearrangement begins with oxidation of the sulfur atom of **3**-methyl ester to sulfoxide **15**. Treatment of this with a trace of acid in refluxing toluene then gives the cepham skeleton. The most likely mechanism involves initial thermal elimination of a sulfenic acid to provide an olefinic intermediate **16**. This then recombines and displaces water to form the cepham cation **17**,

and final elimination of a proton provides the observed product **4** (Scheme 5A). Baldwin and coworkers later investigated related one-electron processes by synthesising a variety of radical precursors (Scheme 5B). In all cases initiation of homolysis led to the same mixture of products (roughly 35% of each diastereomer of **21**) when Ph₃SnH was used. The allyl thiol **22** was formed in the presence of allyltriphenyl tin.[14] It thus appears that regardless of the starting radical, the intermediates probably rearrange to the most stable radical **23c** which then abstracts a hydrogen from Ph₃SnH to form diastereomers of **21**. The more nucleophilic radical **23b** reacts instead with allyltriphenyl tin to give **22**. In principle, thermal heterolytic processes could potentially form the same cationic intermediates suggested for the Morin reaction in these reactions (Scheme 5A), but in the absence of radical initiators no products were formed ruling out this mechanistic possibility.

2.3 Structural information

The crystal structure of the fungal DACS enzyme has not yet been reported, but the structure of the analogous bacterial DAOCS enzyme was determined by Baldwin and coworkers and reported in 1998.[15] Although the enzyme is trimeric in the crystal structures it is thought to function in solution as a monomer. The active site contains the expected iron atom,

Scheme 5 Likely mechanistic courses of the Morin rearrangement and radical reactions reported by Baldwin and coworkers.

Fig. 1 The overall structure of DAOCS showing the active site iron atom, key residues and substrates. Expansion shows ampicillin bound in active site. Coordinates from 1RXG and 1UNB respectively.

1. + αKG;
2. + O₂;
3. Formation of planar peroxo species;
4. Formation of Iron(IV) oxo species;
5. Loss of CO₂ and succinate, addition of substrate;
6. Hydrogen atom abstraction;
7. Formation of thiacyclopropyl radical;
8. Ring expansion;
9. Electron transfer and elimination;
10. Release of product;

Scheme 6 Mechanism of DAOCS deduced from structural analysis of its active site.

This journal is © The Royal Society of Chemistry 2014

Nat. Prod. Rep., 2014, **31**, 1405–1424 | **1409**

bound by two histidines (H183 and H243) and an aspartate (D185) (Fig. 1). The structure also clearly shows α-ketoglutarate (αKG) bound to the iron, ready for reaction with molecular oxygen. Crystals containing substrate analogues such as ampicillin show that the αKG and O_2 must bind and react first, before expulsion of succinate followed by binding of the substrate ready for expansion. As expected, the β-methyl group comes within 3 Å of the likely position of the ferryl oxygen atom, rationalising the high selectivity of the oxidation.[16,17] Thus the currently accepted mechanism (Scheme 6) involves the generation of the iron(IV) oxo species by reaction of the Fe(II) enzyme with α-ketoglutarate and O_2 (steps 1–4). Loss of succinate (step 5) allows substrate binding and the positioning of the β-methyl close to the iron(IV) oxo center. Hydrogen atom abstraction (step 6) is then followed by rearrangement (steps 7 and 8). It is suggested that the final steps involve electron transfer directly to the Fe(III) center, and elimination of a proton to form the product (step 9). Rebound oxygenation prior to this stage, would lead to the shunt product **13** (Scheme 4). Final dissociation of the product (step 10) allows another cycle to begin.

3 Aflatoxins and related systems

Aflatoxin B1 **24** is a potent environmental carcinogen produced by various species of Aspergilli from the polyketide intermediate norsolorinic acid **25**. Its name derives from 'Aspergillus flavus toxin' and A. flavus and other producing-species such as A. parasiticus have been studied in depth. Aflatoxin B1 **24** and related compounds such as sterigmatocystin, produced by A. versicolor have been the focus of detailed biosynthetic study. Over the years classical isotope feeding,[18] genetic[19] and enzymological[20] studies have provided a detailed view of the overall biosynthetic pathway and several of the key steps. Like many other secondary metabolite pathways in fungi, the tailoring steps are mostly oxidative. The biosynthesis of the aflatoxins, however, is remarkable in requiring three oxidative rearrangements. The first of these sets up the key benzobisfuran motif which mediates DNA interaction; the second rearranges the polyketide-derived anthraquinone; and the final rearrangement is a remarkable oxidative ring contraction to form the cyclopentanone of **24**. Indeed the number and complexity of the rearrangements undergone renders **24** almost unrecognisable as a polyketide and it is a testament to the skill of early workers that much of the pathway was deduced from isotopic feeding experiments and the study of blocked mutants.

3.1 Formation of the benzobisfuran

Vederas performed labelling studies with a blocked mutant of A. parasiticus and showed that averufin is derived from acetate and atmospheric oxygen (Scheme 7A).[21] Complementary feeding experiments from the groups of Simpson[22] and Townsend[23–26] using synthetic selectively isotope-labelled averufins then proved that averufin **26** is a precursor of aflatoxin B1 **24** (Scheme 7B). These experiments also showed that the two tail (C-5′ and C-6′) carbons of averufin **26** are lost during biosynthesis, and that C-2 of averufin migrates from an acetate C-1 derived carbon


Scheme 7 (A) Labelling patterns observed during the biosynthesis of aflatoxin B1. Bold bonds indicate intact acetate. Black circles indicate C-1 of acetate. (B) Selective labelling pattern during construction of the benzobisfuran system from averufin – results from 3 independent experiments shown together. C, retention of intact C–O bond observed via dual $^{13}C-^{18}O$ labelling.

in **26** to an acetate C-2 derived carbon in **27** during the rearrangement.

Townsend investigated the rearrangement using a model system in vitro which involved solvolysis of 6,8-di-O-methylnidurufin **28b** and its 2′ epimer 6,8-di-O-methylpseudonidurufin **29b** (Scheme 8).[27,28] Activation of the 2′ hydroxyl to mesylates **28c** and **29c** and treatment at elevated temperature led to a smooth rearrangement in the case of **28c** itself, but not in the case of its epimer **29c**. Neither nidurufin **28a** itself or pseudonidurufin **29a** can be converted to aflatoxin by various strains of A. parasiticus (despite being shown to penetrate growing cells) and so neither are intermediates.[25] It is thus concluded that oxidation of averufin **26** at the 2′ carbon is required for the rearrangement, but that oxygenation does not occur before the rearrangement.

Attempts to investigate the possibility of a radical rearrangement mechanism met with failure starting with 2′-exo-iodo averufin **32**, but treatment of **32** with silver acetate in organic solvent led to a high yield of **33**, which, in turn, could be hydrolysed to **34** under mild conditions (Scheme 9). These observations are consistent with a rearrangement mechanism

1410 | Nat. Prod. Rep., 2014, **31**, 1405–1424

This journal is © The Royal Society of Chemistry 2014

28a, R^1 = H, R^2 = H, nidurufin
28b, R^1 = Me, R^2 = H, 6,8-di-O-methylnidurufin
28c, R^1 = Me, R^2 = SO$_2$Me

29a, R^1 = H, R^2 = Me, pseudonidurufin
29a, R^1 = Me, R^2 = H, 6,8-di-O-methylpseudonidurufin
29b, R^1 = Me, R^2 = SO$_2$Me

Scheme 8 Rearrangement of activated and protected 6,8-di-O-methylnidurufin epimers.

Scheme 9 (A) *In vitro* reactions of 2′-iodoaverufin leading to the hydroxyversicolorone skeleton. (B) Proposed mechanism accounting for the stereoselectivity of the rearrangement. (C) Proposed reaction manifold stemming from cytochrome P450 catalysed hydrogen atom abstraction, followed by rearrangement and hydroxylation.

involving formation of the oxocarbenium ion **35** (Scheme 9B), and it was hypothesised that the biosynthetic reaction is likely to be very similar.

Despite the evidence for a two-electron cationic process obtained from the model reactions *in vitro*, it has more recently been discovered that the enzyme responsible for the conversion of averufin **26** to hydroxyversicolorin **27** *in vivo* is a cytochrome P450 enzyme (StcB)[29] – a class of catalyst most frequently associated with hydrogen atom abstraction (and thus one electron) reactions and oxygenation *via* the accepted oxygen *rebound* mechanism.[30] These observations can be rationalised if the rearrangement is initialised by hydrogen atom abstraction (Scheme 9C) followed by formation of a transient spirocyclopropane **39** stabilised by

delocalisation of the radical into the phenolic system. This could rearomatise to give the oxymethylene radical **40** which could then be hydroxylated to **41**. Elimination of water giving **36** would lead back to the previously proposed 2-electron reaction manifold (Scheme 9B). Early hydroxylation of the initially formed radical **38** would form nidurufin – a minor shunt metabolite of the pathway[31] which is itself not a precursor of hydroxyversicolorone **27**.

3.2 Oxidative rearrangement of versicolorin: formation of the sterigmatocystin skeleton

Hydroxyversicolorone **27** undergoes a series of conventional reactions including Baeyer–Villiger oxidation to form versiconal acetate,[32] hydrolysis to versiconal[24] and finally dehydration to

This journal is © The Royal Society of Chemistry 2014

Nat. Prod. Rep., 2014, **31**, 1405–1424 | **1411**

Scheme 10 Deduced oxidative rearrangement of the versicolorin A anthraquinone **43** to the demethyl sterigmatocystin xanthone **44a**. A, synthetic compounds not incorporated into the pathway; B, deduced pathway consistent with all evidence; C, Results of conversion of versicolorin to methylsterigmatocystin **44c** in deuterated media showing high exchange into the A-ring but not the C-ring.

versicolorin B **42**.[20] Versicolorin B is oxidised to Versicolorin A **43**. Both anthraquinones **42** and **43** can undergo oxidative rearrangement to form the xanthone skeleton. The pathways are identical and the discussion here will focus on the rearrangement of **43** (Scheme 10). Two genes have been implicated in this process, *aflN* and *aflM* which encode a cytochrome P450 oxygenase and an NADPH dependent oxidoreductase respectively.[33] Since the overall conversion of **43** to **44** requires two oxidations and one reduction it appeared likely that AflN should act twice, but the order of the reactions was not obvious from the knockout experiments. Townsend and coworkers synthesised **45**, the putative product if the reduction occurred first, but this was not transformed to aflatoxin B1 **24** by whole cells of

A. parasiticus (Scheme 10A). Likewise, the products of putative early Baeyer–Villiger reaction (carboxy benzophenones such as **46**) were not transformed either.[34] Facile incorporation of demethyl sterigmatocystin **44a**, but not of its 9-hydroxylated analogue showed that **44a** was on the direct pathway to aflatoxin B1 **24**, and that reduction could not occur as the final step of the rearrangement.

These observations led to the development of a new hypothesis in which initial oxidative dearomatisation of the anthraquinone provides the first intermediate (**47**) during the rearrangement (Scheme 10B).[35] Second step reduction to **49** and tautomerisation to **50** provides the substrate for a more conventional Baeyer–Villiger type oxidation as the final redox

1412 | *Nat. Prod. Rep.*, 2014, **31**, 1405–1424

This journal is © The Royal Society of Chemistry 2014

step giving **51**. This must then be followed by hydrolysis, ring closing, decarboxylation and consequent rearomatisation to form the xanthone skeleton of **44a**. While significant synthetic chemistry was achieved to access various putative intermediates, none was ever positively incorporated into aflatoxin B1 **24** *in vivo*. Furthermore it proved impossible to synthesise or observe any intermediate between **43** and **44a** in Scheme 10. However, evidence for the pathway was accumulated from observations of incorporations of deuterium from labelled media specifically at C-8, C-9 and C-10 of **44c**, supporting dearomatisation of the A-ring ring (Scheme 10C). Furthermore, Baeyer–Villiger reaction of the dearomatised intermediate **50** is likely to be energetically more feasible than that of the anthraquinone **43** – a species which is known as a very poor substrate for this reaction *in vitro*.[36]

### 3.3 Formation of the aflatoxin B1 and G1 skeletons

Unremarkable methyltransferase steps form sterigmatocystin **44b** and *O*-methylsterigmatocystin **44c** before the final oxidative rearrangements. Sankawa and coworkers showed that deuterium from [2-^{2}H$_3$] acetate labels sterigmatocystin **44b** as shown in Scheme 11.[37] Simpson and coworkers then followed the incorporation of [2-^{2}H$_3$] acetate into aflatoxin B1 **24** and showed that C-5 of **24** becomes deuterated. Since this carbon derives from C-1 of acetate there must have been a 1,2-deuterium migration during biosynthesis and this was rationalised as being due to an NIH-shift (Scheme 11).[38] This work also

implicated 11-hydroxy-*O*-methylsterigmatocystin (HOMST) **54b** as a pathway intermediate, but at this stage this could not be proven.

Further evidence for the intermediacy of HOMST **54b** came from experiments by Townsend and coworkers who produced sterigmatocystin **44b** from [2-^{14}C]-acetate and chemically converted it to *O*-methylsterigmatocystin **44c** which was then used in cell-free assays with a mutant of *A. parasiticus* blocked in the early part of the pathway.[39] The exogenous compound was converted to aflatoxin B1 **24**, and ^{14}CO$_2$ was released (Scheme 11). Rigorous controls showed that the label was not released as formate or formaldehyde. Radiochemical quantification of the CO$_2$ and **24** produced showed the expected ratio of 1 : 7. The results showed that the released carbon must be oxidised *twice* as shown in Scheme 11. Further isotopic labelling experiments directly probed the source and fate of the oxygen atoms used in the rearrangement with ^{18}O$_2$. Aflatoxin B1 **24** produced under these conditions contained ^{18}O at carbons 1, 8 and 16 in accord with the pathway set out in Scheme 11.[40]

No further progress was made in understanding this step until the gene *ord*1 was identified by knockout and expression as being involved in the conversion of *O*-methylsterigmatocystin **44c** to aflatoxin B1 **24** in 1997.[41] The *ord*1 gene encodes a cytochrome P450 enzyme, and Townsend and coworkers showed that the Ord1 protein is the sole catalyst required for the remarkable transformation of **44c** to **24**.[42] The *ord*1 gene was expressed in yeast and its product shown to be highly active in its ability to convert *O*-methylsterigmatocystin **44c** to **24** in both whole cells and cell-free preparations. HOMST **54a** was synthesised and also shown to be an efficient precursor to **24**, placing it firmly on the direct pathway. Although no other intermediates have been isolated, the mechanism shown in Scheme 12 has been deduced from all the available evidence.[41]

A final oxidative rearrangement during the formation of aflatoxin G1 **63** has also recently been investigated. Evidence for the involvement of another cytochrome P450 enzyme, CypA, has been gathered by extensive KO and expression studies, as well as *in vitro* experiments. The evidence suggests that **60**, or one of its precursors **58** or **59**, is epoxidised leading to the formation of **61**. Rearrangement and loss of methanol then leads to Aflatoxin G1 **63**.[43]

Scheme 11 Rationalisation of results obtained when feeding [2-^{2}H$_3$] acetate to *A. parasiticus*. Dark circles indicate positions of acetate C-1-derived carbons. Hollow circle shows fate of C-11. * = atmospheric oxygen.


This journal is © The Royal Society of Chemistry 2014

Nat. Prod. Rep., 2014, **31**, 1405–1424 | **1413**

Scheme 12 Proposed final oxidative rearrangement pathways during the formation of aflatoxins B1 **24** and G1 **63**. HOMST **54a** is the only intermediate which has been isolated and characterised.

4 Spirocycles and related systems

Filamentous fungi produce a wide range of spirocyclic polyketides, meroterpenoids and alkaloids, exemplified by geodin **64**, griseofulvin **65**, austinol **66** and notoamide B **67**.

4.1 Geodin

Townsend and Henry speculated about the biosynthesis of geodin based upon the conclusions gained from the study of the xanthone formation during aflatoxin biosynthesis.[34] It was already known that the polyketide emodin **68** is methylated to form questin **69**.[44] It was proposed that questin **69** then

Scheme 13 Biosynthesis of geodin **64** in *Aspergillus nidulans*.

1414 | *Nat. Prod. Rep.*, 2014, **31**, 1405–1424

This journal is © The Royal Society of Chemistry 2014

Scheme 14   Biosynthesis of griseofulvin **65** in *Penicillium aethiopicum*.

undergoes and AflN-like oxidative dearomatisation and Baeyer–Villiger/hydrolysis sequence to form cyclohexadienone **72**, which is then reduced in a reaction analogous to that performed by AflM. The produced alcohol **73** cannot simply dehydrate like **49** (Scheme 10) because the hydroxyl is methylated, but an alternative dehydration gives desmethylsulochrin **74**.

Scheme 15   Origin of carbon and oxygen atoms during the synthesis of austinol **66a**, and deduced chemical transformations during the oxidative rearrangement of the A-ring.

Scheme 16 Possible mechanisms leading to the formation of the austinol A-ring.

*O*-Methylation and aromatic halogenation is then followed by a final oxidative step to form (+)-geodin **64** (Scheme 13). The oxidative spirocycle-formation is catalysed by a rare blue-copper enzyme.[45] All key features of this pathway have been supported by the recent work of Larsen, Mortensen and coworkers who identified a putative geodin biosynthetic gene cluster in *Aspergillus nidulans* which contains the expected *aflN* homologue (*gedK* = ATEG_08459).[46]

4.2   Griseofulvin

At first-glance the structure of griseofulvin **65** would suggest a biosynthetic pathway similar to that of geodin **64**. However

Tang and coworkers recently completely elucidated the biosynthetic pathway to **65** and showed that yet another oxidative process is used to form the core spirocycle – although oxidative dearomatisation once again plays a key role.[47] In this case the carbon atoms are again provided by a polyketide synthase (GsfA), but rather than an anthraquinone, the PKS forms a benzophenone (griseophenone) skeleton **76** directly. This is doubly *O*-methylated and chlorinated, before a cytochrome P450 enzyme, GsfF, catalyses probable epoxidation, spirocycle formation and final dehydration to **81** (Scheme 14). Biosynthesis is then completed by a third *O*-methylation and reduction of the dienone.

Scheme 17 Compounds derived from brevianamide F and the spirotryprostatin pathways.

4.3 Austin and related compounds

In the case of austinol **66a**, and related compounds such as the andibenins,[48] extensive isotopic labelling studies, principally by the groups of Simpson and Vederas,[49] revealed the meroterpenoid nature of the carbon skeleton. The labelling evidence shows that dimethylorsellinic acid, produced by a non-reducing fungal PKS from acetate and methionine, condenses with a sesquiterpenoid, and a typical oxidative cyclisation probably leads to the early intermediate **84a** (Scheme 15). Oxidative rearrangement of the orsellinate-derived ring then sets up the D-ring of **85**, ready for a Baeyer–Villiger type oxidation. The A-ring of **85** must also be rearranged, and subjected to another Baeyer–Villiger type oxidation.

Genetic investigations in various aspergillus species have revealed the gene cluster(s) involved in the biosynthesis of austin **66b** and related metabolites.[50,51] Very recently Abe and

coworkers have discovered the molecular details of the oxidative rearrangements during the construction of the key spirocyclic A-ring of austinol **66a**.[52] Protoaustinoid A **86** was supplemented to cultures of *Aspergillus oryzae* in which various oxidative genes from the biosynthetic cluster had been heterologously expressed. In a control reaction it was shown that **86** was not transformed by any endogenous *A. oryzae* enzymes, but incubation with *A. oryzae/ausB* led to the formation of **87** (Scheme 15). Addition of *ausE* resulted in the production of the shunt metabolite austinoid C **92**, but further addition of *ausC* led to formation of preaustinoid A3 **91**. The reconstructed pathway thus appears to involve initial 5′ hydroxylation (AusB), followed by oxidation of the 3-hydroxyl to a ketone (AusE). AusC then catalyses a Baeyer–Villiger oxidation to give preaustinoid A1 **89**, but this is then followed by two more oxidations catalysed by AusE which form the αβ-unsaturated system of preaustinoid A2

Scheme 18 Proposed oxidative rearrangement mechanisms during spirotryprostatin biosynthesis.

90 and then the spirocycle itself (Scheme 15). AusE encodes a non-heme iron oxygenase, and this is clearly multifunctional, catalysing 3 separate reactions around the A-ring.

The mechanism proposed for the spirocycle formation (Scheme 16) involves presumed hydrogen atom abstraction at the 5-position of preaustinoid A2 **90**, followed by top-face hydroxylation. Top-face hydroxylation is assumed because the oxidative iron-oxo center of AusE must be above the ring for it to successfully oxidise berkeleyone A **87** in the first reaction. Suprafacial elimination/bond migration are then proposed to cause the ring contraction (Scheme 16). This mechanism appears problematic because of stereoelectronic considerations regarding the *syn*-arrangement of the migrating bond and the oxy-iron leaving group. An alternative mechanism could involve initial rearrangement of the 5-radical *via* a methylene cyclopropane intermediate **95**, followed by later rebound hydroxylation to form **97**. This could then undergo allowed *syn* elimination to form **91** (Scheme 16). However, current evidence does not allow these mechanistic alternatives to be distinguished.

Finally, AusJ has been identified as the enzyme responsible for the ring contraction of the D-ring in the pathway. Directed knockout of *ausJ* gave preaustinoid A3 **91** as the product,[50] although further mechanistic studies have not yet been reported.

4.4 Prenylated indole alkaloids

Recent advances in genome sequencing technology have provided rapid access to the biosynthetic gene clusters responsible for the production of fungal prenylated indole alkaloids such as the notoamides, spiroprostatins, fumi-tremorgins and tryprostatins (Scheme 17). Genetic studies have been supported by *in vitro* assays which have delineated the activities of the enzymes responsible for the key oxidative rearrangements. The common intermediate in both pathways is the diketopiperazine brevianamide F **98** which is produced by a non-ribosomal peptide synthetase from L-tryptophan and L-proline.[53] The key rearrangement reactions in the notoamide pathway were reported by Sherman, Williams and coworkers in 2012, while Watanabe and coworkers reported the related spi-rotryprostatin rearrangements in 2013.

Heterologous expression of five genes from the fumi-tremorgin gene cluster in *Aspergillus niger* (*ftmA–E*, encoding the NRPS, prenyltransferase, tryptophan hydroxylase, *O*-methyl-transferase and piperidine synthase respectively) yielded fumi-tremorgin C **100** (Scheme 17). Intermediates for *in vitro* studies were produced by appropriate expression of combinations of the genes in yeast. Expression of *ftmA–E* plus the gene *fqzB*, which encodes an FAD-dependent monooxygenase, led to the production of spirotryprostatin A **101** (Scheme 17) indicating that this is the spirocycle forming enzyme.[54] The mechanism is proposed to involve epoxidation of the indole 2,3-olefin, fol-lowed by pinacol-type rearrangement (Scheme 18A/B). *In vitro*, tryprostatin B **99a** gave only dihydroxy products when it was incubated with FqzB, resulting from epoxide hydrolysis (Scheme 18A). However the *p*-methoxy analogue tryprostatin A **99b** underwent a mixture of FqzB-catalyzed oxidative rear-rangement and dihydroxylation showing that participation of the *p*-methoxy group is required for the rearrangement.

Scheme 19 Oxidative rearrangements involved in notoamide biosynthesis.

1418 | *Nat. Prod. Rep.*, 2014, **31**, 1405–1424

This journal is © The Royal Society of Chemistry 2014

These results suggested that FqzB cannot be involved in the biosynthesis of spirotryprostatin B **102** which lacks a *p*-methoxy group. The gene *ftmG* (encoding a cytochrome P450 monooxygenase) was identified as providing the catalysis for this conversion: heterologous expression of *ftmABE* provided demethoxyfumitremorgin C **103** (Scheme 17), and addition of *ftmG* provided mono- and dihydroxylated shunt products **104** and **105**, as well as the spirocyclic spirotryprostatin B **102** (Scheme 17). In this case the mechanism of rearrangement must be more complex, probably involving a double oxidation series, by the usual hydrogen atom abstraction/oxygen rebound route, before a concerted rearrangement and elimination (Scheme 18B). Interestingly, while FqzB is selective in that it requires the *p*-methoxy for correct reaction, FtmG can process both substrate series.

The notoamides differ from the spirotryprostatins in being doubly prenylated. Importantly C-2 alkylation, while occurring with the same regiochemistry with respect to the indole, occurs with inverted regioselectivity[55] at the dimethylallyl unit and notoamide E **108** is the key intermediate in the pathway.[56,57] Feeding studies have been performed which showed the intermediacy of a pinacol-type rearrangement.[58] The *notB* gene encodes an FAD-dependent monooxygenase which has been identified at the catalyst for this step.[59] *In vitro*, NotB converts notoamide E **108** to notoamides C **113** and D **111** (Scheme 19A). The mechanisms of these transformations are again likely to involve epoxide intermediates, with the migration assisted by the *para*-oxygen. Interestingly these compounds are not precursors of the more complex family members such as notoamide B **67** – here the oxidative rearrangement occurs later. In this pathway the achiral azadiene intermediate **114** is believed to undergo intramolecular Diels–Alder reaction. Different fungi appear to possess different selectivities for this cyclo-addition and from this point *enantiomeric pathways* are known in different organisms.[60] The pathway is thought to proceed *via* stephacidin A **115** which undergoes oxidative rearrangement catalysed by NotI (FAD monooxygenase) to give notoamide B **67** (Scheme 19B).

5 Tropolones and related systems

Tropolones are relatively common fungal secondary metabolites – indeed the first natural product discovered to be a tropolone was stipitatic acid **116** from *Talaromyces stipitatus* which was reported by Raistrick and coworkers in 1942,[61] although the structure was not elucidated until Dewar's seminal publication

Scheme 20 Proposed biosynthesis of xenovulene A **117** *via* a tropolone intermediate and consecutive ring contractions.

This journal is © The Royal Society of Chemistry 2014

Nat. Prod. Rep., 2014, **31**, 1405–1424 | **1419**

Scheme 21 Biosynthesis of tropolones.

of 1945.[62] The biosynthesis has been extensively investigated using isotopic labels which showed that oxidative rearrangement of an aromatic polyketide derived from acetate and methionine formed the tropolone ring.[63] However the molecular details of the pathway have been only recently elucidated.[64]

Xenovulene A **117** (Scheme 20) from the fungus *Acremonium strictum* is a potent antagonist of the GABA$_A$ receptor.[65] Isotopic labelling studies showed it is derived from a methylated polyketide fused to humulene. Simpson and coworkers suggested a route involving oxidative ring expansion to a tropolone, followed by sequential ring contractions to **117** (Scheme 20).[66] Although a full genome sequence of the producing strain is not yet available, a traditional genome library-probing approach afforded a *ca* 22 Kb genomic dna fragment containing genes encoding a non-reducing PKS (*aspks*1), an FAD-dependent monooxygenase, a non-heme iron monooxygenase and a cytochrome P450 monooxygenase. Expression of *aspks*1 showed it produced methylorcinaldehyde **129**, but further elucidation of the xenovulene gene cluster was not possible because of the difficulty in obtaining targeted knockouts.[67]

However, knowledge of the sequence of the xenovulene PKS allowed the sequenced genome of *T. stipitatus* to be mined. Although four *T. stipitatus* PKS genes are closely related to *aspks*1, only one (*tropA*) is clustered with a similar array of monooxygenases. Targeted knockout of *tropA* proved it was involved in the biosynthesis of stipitatic acid **116**, and heterologous expression of *tropA* showed it encoded the synthesis of methylorcinaldehyde **129** (Scheme 21).[68] The next catalyst in the sequence is TropB which is an FAD-dependent monooxygenase

which oxidatively dearomatises the ring to afford the cyclohexadione **130**. Once the ring is dearomatised it is then subject to a second oxidation catalysed by TropC, a non-heme iron monooxygenase. This enzyme must oxidise the methyl group and possible mechanisms could include a 1-electron rearrangement pathway, followed by oxygen rebound and elimination, or a hydroxylation, followed by a two-electron rearrangement and iron assisted elimination (Scheme 21). TropC thus provides stipitaldehyde **134** as the first tropolone. A cascade of further oxidations to form the maleic anhydride of stipitatonic acid **136** is then set in train by TropD, a cytochrome P450 monooxygenase. Discovery of the activity of TropB revealed that oxidative dearomatisation also lies behind the biosynthesis of other well-known fungal metabolites including the sorbicillinoids[69] and the azaphilones.[70]

6 2-Pyridones

Acyl tetramic acids are common fungal metabolites, derived from amino acids and polyketides. Fungal 2-pyridones, such as tenellin **137** (Scheme 22), are also derived from amino acids and polyketides. Leete, Vining, Wright and coworkers showed through elegant double ^{13}C labelling experiments that in the case of tenellin the amino acid undergoes intramolecular rearrangement, but that this could occur either before, or after linkage to the polyketide.[71] O'Hagan, Cox and coworkers showed that the rearrangement likely occurs after linkage of the amino acid and polyketide, implicating the tetramic acid pretenellin A **138a** as an intermediate.[72]

1420 | *Nat. Prod. Rep.*, 2014, **31**, 1405–1424

This journal is © The Royal Society of Chemistry 2014

Scheme 22 Oxidative rearrangements during the biosynthesis of 2-pyridones. (a) (Tenellin) series: R = CHCHC(Me)CHCH(Me)CH$_2$Me; (b) (aspyridone) series R = CH(Me)CH$_2$CH(Me)CH$_2$Me.

More recently, cloning of the tenellin biosynthetic gene cluster[73] has revealed that the iterative PKS–NRPS hybrid TenS synthesises pretenellin A **138a**.[74] This then undergoes clean oxidative rearrangement catalysed by the cytochrome P450 monooxygenase TenA to form pretenellin B **140a**.[75] The related compound aspyridone is produced in a similar fashion – the hybrid PKS–NRPS ApdS produces the tetramic acid preaspyridone A **138b** which undergoes oxidative ring expansion

Scheme 23 Proposed oxidative rearrangement during the biosynthesis of strobilurin A **145**.

This journal is © The Royal Society of Chemistry 2014

Nat. Prod. Rep., 2014, **31**, 1405–1424 | **1421**

catalysed by ApdE.[76] However, in this case ApdE catalysis leads to the formation of three compounds. It appears that while ApdE can catalyse the same ring expansion as TenA giving **140b**, it can also produce two other compounds. The first of these is the benzylic alcohol **139b** which presumably arises through simple hydroxylation, while the second compound **141b** is dephenylated.

These observations are consistent with a mechanism in which the cytochrome P450 initially abstracts a hydrogen atom to give a benzylic radical **142ab**. This may be long-lived enough to rearrange *via* an oxy-cyclopropane radical intermediate **143ab**. The final step may be oxygen rebound followed by elimination to form the aromatic pyridone ring. In the case of **139b**, simple early oxygen rebound can give the alcohol. A related oxygenation at the ring quaternary carbon would lead to a compound which could undergo a concomitant ring expansion and dephenylation. Further details about the mechanisms of TenA and ApdE have not been elucidated since the proteins cannot yet be obtained in soluble form.

7 Strobilurins

Strobilurins (and the closely-related mucidins and oudemansins) such as strobilurin A **145** are potent antifungal compounds produced by basidiomycetes. Numerous compounds are known, but all feature the unusual β-methoxyacrylate moiety – and this has been shown to be the pharmacophore.[77] Many commercially valuable fungicides have been produced based on these structures and the class has become prevalent worldwide in agriculture.[78] Labelling studies have shown that strobilurin A **145** is composed of a polyketide, using an unusual (for fungi) phenylalanine-derived starter unit.[79] The β-methoxyacrylate appears to be derived by an oxidative rearrangement of a putative polyunsaturated polyketide precursor (Scheme 23), followed by *O*-methylation. The mechanism may involve epoxidation, followed by pinacol-type rearrangement, however no further details are currently available.

8 Perspective

Oxidative rearrangements are found in all classes of fungal secondary metabolites: polyketides (*e.g.* tropolones, Section 5.0), peptides (*e.g.* β-lactams, Section 2.0), terpenes (*e.g.* austin, Section 4.3) and alkaloids (*e.g.* notoamides, Section 4.4) are all known substrates. The reactions are catalysed in the main by cytochrome P450 and non-heme iron oxygenases, but participation by FAD-dependent oxygenases is also known. Many of the reactions occur on aromatic substrates, and oxidative dearomatisation is a key theme in many reactions where the stability of the aromatic system is broken to enable the rearrangement. These reactions probably occur by epoxidation of the ring (evidenced in some cases by observation of NIH shifts) and often occur in rings which are already electron-rich (*e.g.* sterigmatocystin biosynthesis, Scheme 10). In many other cases the reactions appear to be initiated by hydrogen atom abstraction, as in the classical cases of cephalosporin biosynthesis (*e.g.* Scheme 6). In these reactions formation of a radical allows

rearrangement through adjacent double bonds or heteroatoms, probably followed by late oxygen rebound and elimination (*e.g.* Scheme 9C) – direct electron transfer as observed in the cephalosporin case appears to be rare. It is mechanistically difficult to distinguish various possible reaction manifolds since it is often the case that intermediates cannot be isolated or easily observed, and a key linking theme is that one- and two-electron rearrangement pathways are difficult to discriminate. For example in the cases of hydroxyversicolorone **27**, model reactions *in vitro* suggest a cationic reaction manifold instead of a radical pathway, while conversely genetic data suggest a P450 (and thus possible radical) route. In the case of cephalosporin **6** biosynthesis, *in vitro* model reactions show that *both* radical and cationic pathways could be possible. In the absence of definitive data in many of these systems it may be better to envisage a continuum of possible mechanisms from cationic routes at one extreme, to radical pathways at the other. What is certain is that the electron deficiency caused by the oxidation is a necessary requirement for the rearrangement itself.

Early investigation of the fungal cephalosporin synthase showed that it catalyses sequential oxidations and again this is often the case – AusE catalyses 3 sequential oxidations including alcohol to ketone, desaturation and ring contraction reactions, during the biosynthesis of austinol **66a**. Finally, the range of chemistry precipitated by these enzymes is highly diverse, and it remains extremely challenging to predict the chemical rearrangements from genome sequence data – but rapidly increasing knowledge about many diverse fungal pathways is making such predictions easier and it seems highly likely that oxidative rearrangements will find a place in the toolbox of synthetic biology as they offer rapid routes to highly complex natural products which are still significantly challenging for synthetic chemistry.

9 Notes and references

1 R. B. Hamed, J. R. Gomez-Castellanos, L. Henry, C. Ducho, M. A. McDonough and C. J. Schofield, *Nat. Prod. Rep.*, 2013, **30**, 21–107.
2 M. Kohsaka and A. L. Demain, *Biochem. Biophys. Res. Commun.*, 1976, **70**, 465–473.
3 D. J. Hook, L. T. Chang, R. P. Elander and R. B. Morin, *Biochem. Biophys. Res. Commun.*, 1979, **87**, 258–265.
4 Y. Sawada, N. A. Hunt and A. L. Demain, *J. Antibiot.*, 1979, **32**, 1303–1310.
5 J. E. Baldwin, J. W. Keeping, P. D. Singh and C. L. Vallejo, *Biochem. J.*, 1981, **194**, 649–651.
6 J. E. Baldwin, J. Löliger, W. Rastetter, N. Neuss, L. L. Huckstep and N. De La Higuera, *J. Am. Chem. Soc.*, 1973, **95**, 3796–3797.
7 N. Neuss, C. H. Nash, J. E. Baldwin, P. A. Lemke and J. B. Grutzner, *J. Am. Chem. Soc.*, 1973, **95**, 3797–3798.
8 H. Kluender, C. H. Bradley, C. J. Sih, P. Fawcett and E. P. Abraham, *J. Am. Chem. Soc.*, 1973, **95**, 6149–6150.
9 C. A. Townsend, A. S. Neese and A. B. Theis, *J. Chem. Soc., Chem. Commun.*, 1982, 116.

1422 | *Nat. Prod. Rep.*, 2014, **31**, 1405–1424

This journal is © The Royal Society of Chemistry 2014

10 C. A. Townsend, A. B. Theis, A. S. Neese, E. B. Barrabee and D. Poland, *J. Am. Chem. Soc.*, 1985, **107**, 4760–4767.

11 C. A. Townsend, *J. Nat. Prod.*, 1985, **48**, 708–724.

12 J. E. Baldwin, R. M. Adlington, N. P. Crouch, C. J. Schofield, N. J. Turner and R. T. Aplin, *Tetrahedron*, 1991, **47**, 9881–9900; J. E. Baldwin, R. M. Adlington, R. T. Aplin, N. P. Crouch, G. Knight and C. J. Schofield, *J. Chem. Soc., Chem. Commun.*, 1987, 1651–1654.

13 R. B. Morin, B. G. Jackson, R. A. Mueller, E. R. Lavagnino, W. B. Scanlon and S. L. Andrews, *J. Am. Chem. Soc.*, 1963, **85**, 1896–1897; R. B. Morin, B. G. Jackson, R. A. Mueller, E. R. Lavagnino, W. B. Scanlon and S. L. Andrews, *J. Am. Chem. Soc.*, 1969, **91**, 1401–1407.

14 J. E. Baldwin, R. M. Adlington, T. W. Kang, E. Lee and C. J. Schofield, *J. Chem. Soc., Chem. Commun.*, 1987, 104.

15 K. Valegard, A. van Scheltinga, M. D. Lloyd, T. Hara, S. Ramaswamy, A. Perrakis, A. Thompson, H. J. Lee, J. E. Baldwin, C. J. Schofield, J. Hajdu and I. Andersson, *Nature*, 1998, **394**, 805–809.

16 L. M. Öster, A. C. T. van Scheltinga, K. Valegård, A. M. Hose, A. Dubus, J. Hajdu and I. Andersson, *J. Mol. Biol.*, 2003, **343**, 157–171.

17 K. Valegård, A. C. T. van Scheltinga, A. Dubus, G. Ranghino, L. M. Öster, J. Hajdu and I. Andersson, *Nat. Struct. Mol. Biol.*, 2003, **11**, 95–101.

18 K. Pachler, P. Steyn, R. Vleggaar, P. Wessels and D. Scott, *J. Chem. Soc., Perkin Trans. 1*, 1976, 1182–1195.

19 G. Feng, F. Chu and T. Leonard, *Appl. Environ. Microbiol.*, 1992, **58**, 455–460.

20 R. Minto and C. Townsend, *Chem. Rev.*, 1997, **97**, 2537–2555.

21 J. C. Vederas and T. T. Nakashima, *J. Chem. Soc., Chem. Commun.*, 1980, 183.

22 T. J. Simpson, A. E. de Jesus, P. S. Steyn and R. Vleggaar, *J. Chem. Soc., Chem. Commun.*, 1982, 631.

23 C. A. Townsend, S. B. Christensen and S. G. Davis, *J. Am. Chem. Soc.*, 1982, **104**, 6152–6153.

24 C. A. Townsend, S. B. Christensen and S. G. Davis, *J. Am. Chem. Soc.*, 1982, **104**, 6154–6155.

25 C. A. Townsend and S. B. Christensen, *J. Am. Chem. Soc.*, 1985, **107**, 270–271.

26 C. A. Townsend, S. B. Christensen and S. G. Davis, *J. Chem. Soc., Perkin Trans. 1*, 1988, 839–861.

27 C. A. Townsend, S. G. Davis, M. Koreeda and B. Hulin, *J. Org. Chem.*, 1985, **50**, 5428–5430.

28 C. A. Townsend, Y. Isomura, S. G. Davis and J. A. Hodge, *Tetrahedron*, 1989, **45**, 2263–2276.

29 Y. Wen, H. Hatabayashi, H. Arai, H. K. Kitamoto and K. Yabe, *Appl. Environ. Microbiol.*, 2005, **71**, 3192–3198.

30 J. T. Groves and G. A. Mcclusky, *J. Am. Chem. Soc.*, 1976, **98**, 859–861.

31 D. Kingston, P. N. Chen and J. R. Vercellotti, *Phytochemistry*, 1976, **15**, 1037–1039.

32 S. M. McGuire and C. A. Townsend, *Bioorg. Med. Chem. Lett.*, 1993, **3**, 653–656.

33 N. P. Keller, C. M. Watanabe, H. S. Kelkar, T. H. Adams and C. A. Townsend, *Appl. Environ. Microbiol.*, 1999, **66**, 359–362.

34 K. M. Henry and C. A. Townsend, *J. Am. Chem. Soc.*, 2005, **127**, 3300–3309.

35 K. M. Henry and C. A. Townsend, *J. Am. Chem. Soc.*, 2005, **127**, 3724–3733.

36 B. Franck, V. Radtke and U. Zeidler, *Angew. Chem., Int. Ed. Engl.*, 1967, **6**, 952–953.

37 U. Sankawa, H. Shimada, T. Kobayashi, Y. Ebizuka, Y. Yamamoto, H. Noguchi and H. Seto, *Heterocycles*, 1982, **19**, 1053–1058.

38 T. J. Simpson, A. E. de Jesus, P. S. Steyn and R. Vleggaar, *J. Chem. Soc., Chem. Commun.*, 1983, 338.

39 M. Chatterjee and C. A. Townsend, *J. Org. Chem.*, 1994, **59**, 4424–4429.

40 C. Watanabe and C. A. Townsend, *J. Org. Chem.*, 1996, **61**, 1990–1993.

41 R. Prieto and C. P. Woloshuk, *Appl. Environ. Microbiol.*, 1997, **63**, 1661–1666.

42 D. W. Udwary, L. K. Casillas and C. A. Townsend, *J. Am. Chem. Soc.*, 2002, **124**, 5294–5303.

43 H. Zeng, H. Hatabayashi, H. Nakagawa, J. Cai, R. Suzuki, E. Sakuno, T. Tanaka, Y. Ito, K. C. Ehrlich, H. Nakajima and K. Yabe, *Appl. Microbiol. Biotechnol.*, 2011, **90**, 635–650.

44 Z. G. Chen, I. Fujii, Y. Ebizuka and U. Sankawa, *Arch. Microbiol.*, 1992, **158**, 29–34.

45 K. X. Huang, I. Fujii, Y. Ebizuka, K. Gomi and U. Sankawa, *J. Biochem.*, 1995, **270**, 21495–21502; I. Fujii, H. Iijima, S. Tsukita, Y. Ebizuka and U. Sankawa, *J. Biochem.*, 1987, **101**, 11–18.

46 M. T. Nielsen, J. B. Nielsen, D. C. Anyaogu, D. K. Holm, K. F. Nielsen, T. O. Larsen and U. H. Mortensen, *PLoS One*, 2013, **8**, e72871.

47 R. A. Cacho, Y.-H. Chooi, H. Zhou and Y. Tang, *ACS Chem. Biol.*, 2013, **8**, 2322–2330.

48 T. J. Simpson, S. A. Ahmed, C. R. McIntyre, F. E. Scott and I. H. Sadler, *Tetrahedron*, 1997, **53**, 4013–4034.

49 S. A. Ahmed, F. E. Scott, D. J. Stenzel, T. J. Simpson, R. N. Moore, L. A. Trimble, K. Arai and J. C. Vederas, *J. Chem. Soc., Perkin Trans. 1*, 1989, 807.

50 C.-J. Guo, B. P. Knox, Y.-M. Chiang, H.-C. Lo, J. F. Sanchez, K.-H. Lee, B. R. Oakley, K. S. Bruno and C. C. C. Wang, *Org. Lett.*, 2012, **14**, 5684–5687; A. B. Rodríguez-Urra, C. Jimenez, M. I. Nieto, J. Rodríguez, H. Hayashi and U. Ugalde, *ACS Chem. Biol.*, 2012, **7**, 599–606; M. L. Nielsen, J. B. Nielsen, C. Rank, M. L. Klejnstrup, D. K. Holm, K. H. Brogaard, B. G. Hansen, J. C. Frisvad, T. O. Larsen and U. H. Mortensen, *FEMS Microbiol. Lett.*, 2011, **321**, 157–166.

51 H.-C. Lo, R. Entwistle, C.-J. Guo, M. Ahuja, E. Szewczyk, J.-H. Hung, Y.-M. Chiang, B. R. Oakley and C. C. C. Wang, *J. Am. Chem. Soc.*, 2012, **134**, 4709–4720.

52 Y. Matsuda, T. Awakawa, T. Wakimoto and I. Abe, *J. Am. Chem. Soc.*, 2013, **135**, 10962–10965.

53 S. Maiya, A. Grundmann, S.-M. Li and G. Turner, *ChemBioChem*, 2006, **7**, 1062–1069.

54 Y. Tsunematsu, N. Ishikawa, D. Wakana, Y. Goda, H. Noguchi, H. Moriya, K. Hotta and K. Watanabe, *Nat. Chem. Biol.*, 2013, **9**, 818–825.

This journal is © The Royal Society of Chemistry 2014

Nat. Prod. Rep., 2014, **31**, 1405–1424 | **1423**

55 Y. Ding, J. R. de Wet, J. Cavalcoli, S. Li, T. J. Greshock, K. A. Miller, J. M. Finefield, J. D. Sunderhaus, T. J. McAfoos, S. Tsukamoto, R. M. Williams and D. H. Sherman, *J. Am. Chem. Soc.*, 2010, **132**, 12733–12740.

56 S. Tsukamoto, H. Kato, T. J. Greshock, H. Hirota, T. Ohta and R. M. Williams, *J. Am. Chem. Soc.*, 2009, **131**, 3834–3835.

57 J. M. Finefield, T. J. Greshock, D. H. Sherman, S. Tsukamoto and R. M. Williams, *Tetrahedron Lett.*, 2011, **52**, 1987–1989.

58 H. Kato, Y. Nakamura, J. M. Finefield, H. Umaoka, T. Nakahara, R. M. Williams and S. Tsukamoto, *Tetrahedron Lett.*, 2011, **52**, 6923–6926.

59 S. Li, J. M. Finefield, J. D. Sunderhaus, T. J. McAfoos, R. M. Williams and D. H. Sherman, *J. Am. Chem. Soc.*, 2012, **134**, 788–791.

60 S. Li, K. Srinivasan, H. Tran, F. Yu, J. M. Finefield, J. D. Sunderhaus, T. J. McAfoos, S. Tsukamoto, R. M. Williams and D. H. Sherman, *Med. Chem. Commun.*, 2012, **3**, 987.

61 J. Birkinshaw, A. Chambers and H. Raistrick, *Biochem. J.*, 1942, **36**, 242–251.

62 M. Dewar, *Nature*, 1945, **155**, 50–51.

63 M. O'Sullivan and J. Schwab, *Bioorg. Chem.*, 1995, **23**, 131–143.

64 R. J. Cox and A. Al Fahad, *Curr. Opin. Chem. Biol.*, 2013, **17**, 532–536.

65 A. Ainsworth, M. Chicarelli-Robinson, B. Copp, U. Fauth, P. Hylands, J. Holloway, M. Latif, G. Obeirne, N. Porter, D. Renno, M. Richards and N. Robinson, *J. Antibiot.*, 1995, **48**, 568–573.

66 M. Raggatt and M. Chicarelli-Robinson, *Chem. Commun.*, 1997, 2245–2246.

67 A. M. Bailey, T. J. Simpson, R. J. Cox, K. Harley and E. Skellam, *Chem. Commun.*, 2007, 4053–4055; A. M. Bailey, K. M. Fisch, E. Skellam, D. Ivison, R. J. Cox, C. M. Lazarus and T. J. Simpson, *Chem. Commun.*, 2010, **46**, 5331–5333.

68 J. Davison, A. al Fahad, M. Cai, Z. Song, S. Y. Yehia, C. M. Lazarus, A. M. Bailey, T. J. Simpson and R. J. Cox, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, 7642–7647.

69 A. Al Fahad, A. Abood, K. M. Fisch, A. Osipow, J. Davison, M. Avramović, C. P. Butts, J. Piel, T. J. Simpson and R. J. Cox, *Chem. Sci.*, 2013, **5**, 523–527.

70 A. O. Zabala, W. Xu, Y.-H. Chooi and Y. Tang, *Chem. Biol.*, 2012, **19**, 1049–1059.

71 E. Leete, N. Kowanko, R. Newmark, L. Vining, A. Mcinnes and J. Wright, *Tetrahedron Lett.*, 1975, 4103–4106.

72 R. J. Cox and D. O'Hagan, *J. Chem. Soc., Perkin Trans. 1*, 1991, 2537–2540; M. Moore, R. J. Cox, G. Duffin and D. O'Hagan, *Tetrahedron*, 1998, **54**, 9195–9206.

73 K. L. Eley, T. J. Simpson, A. M. Bailey, L. M. Halo, Z. Song, H. Powles, R. J. Cox and A. M. Bailey, *ChemBioChem*, 2007, **8**, 289–297.

74 L. M. Halo, J. W. Marshall, A. A. Yakasai, Z. Song, C. P. Butts, M. P. Crump, M. Heneghan, A. M. Bailey, T. J. Simpson, C. M. Lazarus and R. J. Cox, *ChemBioChem*, 2008, **9**, 585–594.

75 L. M. Halo, M. N. Heneghan, A. A. Yakasai, Z. Song, K. Williams, A. M. Bailey, R. J. Cox, C. M. Lazarus and T. J. Simpson, *J. Am. Chem. Soc.*, 2008, **130**, 17988–17996.

76 Z. Wasil, K. A. K. Pahirulzaman, C. Butts, T. J. Simpson, C. M. Lazarus and R. J. Cox, *Chem. Sci.*, 2013, **4**, 3845.

77 J. Clough, *Nat. Prod. Rep.*, 1993, **10**, 565–574.

78 H. Sauter, W. Steglich and T. Anke, *Angew. Chem., Int. Ed.*, 1999, **38**, 1329–1349.

79 F. Nerud, P. Sedmera, Z. Zouchová, V. Musílek and M. Vondráček, *Collect. Czech. Chem. Commun.*, 1982, **47**, 1020–1025.

1424 | *Nat. Prod. Rep.*, 2014, **31**, 1405–1424

This journal is © The Royal Society of Chemistry 2014